The signal transduction pathways, orchestrating the differentiation of hematopoietic stem and progenitor cells in response to cytokine stimulation, are strictly controlled by networks of feedback loops, highly selective protein interactions and finely tuned on/off switches. In hematological malignancies, the aberrant activation of signaling pathways is usually associated with mutations in tyrosine kinases. Recently, the role of negative signaling regulators is increasingly being recognized as an alternative mechanism involved in diseases such as leukemias and myeloproliferative neoplasms (MPNs). The adaptor protein LNK (Src homology 2 (SH2)B3) is a negative regulator of cytokine signaling that has an essential, nonredundant role in normal hematopoiesis. Indeed, LNK-deficient mice show marked expansion of early hematopoietic precursors, more mature myeloid and B-lineage lymphoid cells, as well as enhanced hematopoietic reconstitution. Murine models show that loss of LNK enhances the development of MPNs and may have a role in additional pathologies. LNK mutations were recently identified in patients with MPNs, and studies in animal models and hematopoietic cell lines suggest that LNK controls the aberrant signaling pathways induced by activated oncogenic kinases. In addition, genome-wide studies show that LNK is associated with autoimmune and cardiovascular disorders. These findings have implications for the future study of hematopoiesis, as well as for the development of novel stem cell and disease-specific therapies.
INTRODUCTION
Throughout life, hematopoiesis is a continuing process, in which hematopoietic stem cells (HSCs) replenish multilineage progenitors that further differentiate into all lineages of mature blood cells. Cytokines and their cognate receptors are key factors influencing the function and survival of hematopoietic cells. The magnitude and kinetics of cytokine receptor activation is tightly regulated at multiple levels to ensure a proper cellular response and prevent leukemic transformation. Dysregulation of signaling by receptor tyrosine kinases (RTKs), as well as non-RTKs (i.e., Janus kinases (JAKs)) is, a frequent event in cancer, particularly in hematopoietic malignancies. 1, 2 Adaptor proteins that bind RTKs and JAKs have an important role in the control of cytokine signaling pathways. These adaptor proteins usually lack enzymatic activity and instead serve as molecular platforms coordinating signaling events. The Src homology 2 (SH2)B family is a group of adaptor proteins implicated in a broad range of signaling pathways. Among mice deficient for SH2B family members, those who are LNK-deficient have the most prominent aberrations in hematopoiesis. 3, 4 Moreover, LNK mutations have recently been identified in myeloproliferative neoplasms (MPNs) and some leukemias, [5] [6] [7] [8] [9] [10] [11] [12] [13] demonstrating the importance of LNK not only for normal but also for aberrant hematopoiesis, thus forming the rationale for this review.
SH2B FAMILY
The SH2B family of adaptor proteins consists of SH2B1, APS (SH2B2) and LNK (SH2B3). These proteins share a common domain structure ( Figure 1 ) with a N-terminal dimerization domain containing a phenylalanine zipper motif, which mediates homoand heterodimerization of SH2B family members; 14 proline-rich regions; a pleckstrin homology (PH) domain believed to recognize phosphoinositides and control cell membrane localization; a SH2 domain essential for binding phosphotyrosine in target proteins; and a conserved C-terminal CBL recognition motif. SH2B adaptor proteins are implicated in signal transduction pathways downstream of various RTKs, including receptors for insulin, insulin-like growth factor I, nerve growth factor, platelet-derived growth factor (PDGF), fibroblast growth factor, stem cell factor (SCF)/c-KIT and macrophage colony-stimulating factor (M-CSF)/FMS, as well as JAKs. 15, 16 Deletion of SH2B1 in mice results in severe obesity, leptin and insulin resistance, type 2 diabetes and infertility. 17 Genetic studies have also indicated that SH2B1 has a key role in controlling body weight and glucose homeostasis in humans. Deletion of APS does not alter adiposity, energy balance or glucose metabolism, but may negatively regulate leptin and insulin sensitivity under certain conditions. 18 LNK was originally cloned from a lymph node cDNA library and shown to participate in T-cell signaling. 19 Shortly after, two groups generated LNK-deficient mice providing important insights into LNK function in hematopoiesis. 3, 4 Although high levels of LNK are found in non-hematopoietic tissues such as the testis, brain and muscle, the only noticeable phenotypes of Lnk À / À mice are in the hematopoietic compartments. Further studies established LNK as a key hub integrating multiple signaling pathways in the hematopoietic/ immunologic system. 1 Hematology/Oncology, Cedars-Sinai Medical Center, UCLA School of Medicine, Los Angeles, CA, USA and LNK IN NORMAL HEMATOPOIESIS LNK in hematopoietic lineages LNK is highly expressed in multipotent hematopoietic cells and their precursors. Furthermore, expression levels of LNK are regulated during normal hematopoiesis, and enhanced by cytokine stimulation. Although LNK functions as a negative regulator of cytokine signaling in various lineages, the specific pathways targeted by LNK appear to differ between the lineages (Figure 2 ). The most striking features of Lnk À / À mice are profound splenomegaly with extramedullary hematopoiesis. 3, 4 The enlarged spleens of these mice had marked expansion of B lineage lymphocytes resulting in part from hypersensitivity of B cells precursors to SCF. LNK was originally reported to be involved in T-cell receptor signal transduction; yet, T-cell development is unaffected in LNK-deficient mice.
Several studies demonstrated a critical role of LNK in controlling self-renewal and quiescence of HSCs. [20] [21] [22] [23] [24] LNK-deficient mice have a 10-15-fold increase in HSC numbers with enhanced multi-lineage repopulation after bone marrow (BM) transplantation. LNK constrains quiescence and self-renewal of HSCs/ hematopoietic progenitor cell (HPCs), predominantly through thrombopoietin/JAK2 signaling. LNK-deficient mice also display a 3-5-fold increase in circulating white blood cells and platelets, as well as accumulation of erythroid and megakaryocytes cells in the BM. These changes are due to hypersensitivity to signaling by erythropoietin and thrombopoietin. 25, 26 Hematopoietic progenitors in Lnk À / À mice show hypersensitivity to several other cytokines such as interleukin (IL)-3 and IL-7.
In murine platelets, LNK regulates integrin aIIbb3 outside-in signaling, leading to stabilization of thrombus development in vivo. 27 Involvement of LNK in integrin-mediated signaling pathways was also reported the in maturation process of megakaryocytes, where LNK functions during cell adhesion and is involved in a crosstalk between integrin-and cytokine-mediated signaling. 28 LNK also has a role in mast cell development by attenuating signaling of c-KIT. 29 Compared with wild-type (WT) cells, Lnk À / À BM mast cells display increased SCFdependent proliferation and migration. In macrophages, LNK regulates signaling by M-CSF. 30 Clonogenic assays demonstrated elevated number of macrophage colony-forming cells in Lnk À / À BM. In addition, production of reactive oxygen species is increased in Lnk À / À macrophages, and LNK inhibits M-CSF-induced migration of macrophages.
LNK in non-hematopoietic BM cells Non-hematopoietic (stromal) BM cells consist of a heterogeneous cell population, including fibroblasts, endothelial cells, osteoblasts and osteoclasts, providing the structural microenvironment that facilitates hematopoiesis. In addition to its strong expression in hematopoietic cells, LNK is also expressed in non-hematopoietic BM cells. The aorta-gonad-mesonephros region is the first intraembryonic site for definitive hematopoiesis and LNK was found to be a negative regulator of hematopoiesis in this region. 31 LNK was detected in aorta-gonad-mesonephros endothelial cells and its expression pattern overlapped with that of CD34, suggesting that LNK might be involved in hematopoietic cell development from endothelial precursors. In addition in endothelial cells, the proinflammatory cytokine tumor necrosis factor-a, through a phosphatidylinositol 3-kinase-dependent signaling pathway, rapidly phosphorylates and subsequently upregulates LNK. 32 In turn, LNK negatively regulates tumor necrosis factor signaling. Adhesion and migration of endothelial cells is also affected by LNK. Following b1-integrin activation, LNK is rapidly phosphorylated leading to a signaling cascade resulting in increased cell adhesion and reduced cell motility. 33 LNK also has a pivotal role in specific modulation of cell growth, endothelial commitment and mobilization of endothelial progenitor cells (EPCs) from BM into the peripheral blood. 34 Loss of LNK in mice increases EPC kinetics in response to ischemia-related cytokines (vascular endothelial growth factor, stromal cell-derived factor-1, granulocyte CSF and SCF) enhancing neovascularization. In addition, LNK deficiency increases the commitment of c-KIT-positive, Sca-1-positive and lineage marker-negative (KSL) cells to EPCs. 35 Likewise, vasculogenesis/angiogenesis and osteogenesis are augmented in LNKdeficient mice by the mobilization and recruitment of HSCs/EPCs also via activation of the SCF/c-KIT signaling pathway. 36 In addition, osteoblasts from LNK-deficient mice show a greater potential for terminal differentiation in response to signaling by SCF/c-KIT in vitro. Table 1 ). The interaction between LNK and JAK2 is wellcharacterized. JAK2 is a cytoplasmic non-receptor TK that has a crucial role in cytokine signaling during hematopoiesis. JAK2
associates with the juxtamembrane region of homodimeric receptors including erythropoietin R, myeloproliferative leukemia (MPL) (thrombopoietin R), G-CSF R and IL-3R. Ligand binding to the receptor results in JAK phosphorylation, recruitment of STAT proteins and activation of downstream signaling pathways. LNK, as well as the other SHB family members (SH2B1 and APS), via their SH2 domain directly bind the phosphorylated tyrosine residue 813 of activated JAK2 (Figure 3a) . 15, 24, 37 Interestingly, while LNK is a negative regulator of JAK2, SH2B1 and at least in some contexts, APS act as potent activators of JAK2 signaling. Similar to other negative regulators, such as CIS and SOCS proteins, LNK mRNA and protein expression is induced following JAK2 activation.
9,38 LNK, therefore, is part of a negative feedback loop that controls the recptor JAK2/STAT signaling in hematopoiesis. In HSCs, the LNK-JAK2 interaction is further negatively regulated by 14-3-3 adaptor proteins; LNK binds to 14-3-3, and this abrogates the LNK-JAK2 interaction, thereby elevating the inhibitory function of LNK in JAK2 signaling. 39 Although earlier studies showed that tyrosine phosphorylations, particularly the conserved tyrosine in the C-terminal domain of LNK, are important for LNK inhibitory functions, binding of 14-3-3 requires two serine phosphorylation sites in LNK, which are phosphorylated by glycogen synthase kinase 3 and protein kinase A. Together, these finding suggest that LNK is a central signaling node allowing the integration of multiple signaling pathways.
c-KIT was the first cytokine receptor identified as a direct target of LNK. Studies by us and others pinpointed the LNK-c-KIT interaction to the phosphorylated tyrosine 568 in the juxtamembrane domain of c-KIT and the SH2 domain of LNK (Figure 3b) . 29, 40 LNK negatively modulates SCF-dependent signaling pathways involved in proliferation and migration of mast and primary hematopoietic cells. c-KIT is a member of the RTK subclass III family, which includes FMS, FMS-like TK 3 (FLT3) and the receptors for PDGF A and B (PDGFRA and PDGFRB). The Y568 amino acid found in c-KIT is conserved among RTK III family members (Figure 3c ), and we hypothesized that LNK might similarly bind and regulate additional RTK III members. Indeed, LNK binds to FMS and inhibits M-CSF-induced signaling and migration in macrophages. 30 LNK also binds PDGFRA and PDGFRB, and LNK overexpression inhibits PDGF-dependent proliferation of hematopoietic Ba/F3 cells. 41 LNK interacts with FLT3, and FLT3 activation and downstream-induced signaling are suppressed by LNK in 32D hematopoietic cells. 42 In addition, loss of LNK enhances expansion of HPCs stimulated by FL ligand. The SH2 domain is the main LNK domain involved in the LNK interactions with RTK III, as well as JAK2, and is required for the inhibitory effects of LNK.
Recently, LNK was reported to interact with two additional TKs. In endothelial cells, LNK interacts with the integrin-linked kinase, involved in integrin-mediated signal transduction pathways. 33 Through its interaction with integrin-linked kinase, LNK controls cell adhesion and migration. In neuronal cells, LNK binds to phosphorylated nerve growth factor receptor, TRKA. 43 Overexpression of LNK inhibits nerve growth factorinduced differentiation of PC12 neural cells and reduces neurite outgrowth of primary cortical neurons.
Taken together, LNK is emerging as an important negative regulator involved in restraining multiple signaling pathways critical to hematopoietic homeostasis in various lineages (Figure 4) .
LNK IN HEMATOPOIETIC NEOPLASMS
The World Health Organization classification of myeloid malignancies includes five major subgroups: 1. MPNs, 2. myelodysplastic syndromes (MDS), 3. MDS/MPNs, 4. myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or fibroblast growth factor R1 and 5. acute myeloid leukemia (AML). 44 TK signal transduction pathways are often altered in these diseases, and LNK has been suspected to have a role in their pathogeneses. Interestingly, a number of features displayed by LNK-deficient mice are reminiscent of the myeloproliferative abnormalities found in MPN patients, i.e., hypersensitivity to cytokines, splenomegaly together with fibrosis, thrombocytosis and extramedullary hematopoiesis, as well as increased number of multilineage, erythroid and megakaryocytic clonogenic cells.
MPN includes chronic myelogenous leukemia (CML), also known as BCR/ABL1-positive MPNs, classic BCR/ABL1-negative MPNs: polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF), as well as nonclassic MPNs (including systemic mastocytosis, chronic eosinophilic leukemia, chronic myelomonocytic leukemia and unclassifiable MPNs). 45 The activating JAK2V617F mutation is the most prevalent mutation in BCR-ABL1-negative MPNs, detected in virtually all PV cases and in about half of the ET and PMF cases. After the discovery of JAK2V617F, investigators began searching for other mutations relevant to JAK signaling that might contribute to MPN pathogenesis. Indeed, the identification of rare MPL receptor and JAK2 exon 12 mutations were soon discovered. Genome-wide studies identified a number of novel MPN-associated genes including IKZF1, CBL, IDH1/2, EZH2, ASXL1, TET2, as well as LNK.
LNK regulation of oncogenic TKs in myeloid cells
Although LNK mutations occur at a low frequency in MPNs, LNK may regulate the abnormal signaling pathways induced by oncogenic TKs (Table 2) . LNK binds to and negatively regulates MPN-associated mutant MPL and JAK2 alleles, including MPLW515L, JAK2V617F and JAK2K539L. 9, 38, 46 We found that LNK also interacted with and was phosphorylated by JAK3, as well as by JAK3A572V, an activating JAK3 mutation associated with acute megakaryoblastic leukemia. 47 LNK mRNA is overexpressed in MPN patients and positively correlates with the JAK2V617F allele burden. 9, 48 Studies in hematopoietic cell lines showed that LNK together with MPL and JAK2 are involved in a finely controlled feedback mechanism implicated in megakaryopoiesis, where changes in LNK expression modulate JAK2/JAK2V617F-mediated signaling. In a murine model, loss of LNK accelerates and exacerbates oncogenic JAK2 (either JAK2V617F or the TEL/JAK2 fusion)-induced myeloproliferative diseases. 49 The BCR/ABL1 fusion gene is the hallmark of CML. Although LNK does not interact with BCR/ABL1, it does inhibit proliferation of BCR/ ABL1-positive hematopoietic cells. 48 LNK-growth inhibition activity is associated with downregulation of STAT5, a key mediator of the pathogenesis of CML. Furthermore, in a murine model for CML, LNK deficiency cooperates with the BCR/ABL1 oncogene. 49 Thus, LNK regulates aberrant signal transduction pathways in both BCR/ABL1-negative and -positive MPNs. Notably, elevated levels of LNK mRNA are also found in MDS and AML cells, suggesting that LNK may influence not only the development of MPNs but also that of other hematopoietic malignancies. 48 As discussed above, we have shown that LNK associates with and negatively regulates RTK III family members. We found similar interactions between LNK and a number of mutant RTK III alleles present in hematopoietic disorders (Table 2 ). FIP1L1/PDGFRA fusion protein is found in chronic eosinophilic leukemia and systemic mastocytosis patients; TEL/PDGFRB is associated with chronic myelomonocytic leukemia. The growth of hematopoietic 32D cells transformed by either FIP1L1/PDGFRA or TEL/PDGFRB was inhibited by overexpression of LNK, and this effect was dependent on the SH2 domain of LNK. 41 Interestingly, LNK can inhibit growth of cells transformed by either FIP1L1/PDGFRA or TEL/PDGFRB; nevertheless in co-expression experiments, LNK only interacts with and is phosphorylated by FIP1L1/PDGFRA but not Growth factor/cytokine receptor Integrin Migration Adhesion Thrombosis Proliferation Apoptosis Inflammation Self renewal Figure 4 . LNK is part of negative feedback loops in signaling pathways that control various cellular processes critical for hematopoiesis. A full colour version of this figure is available at the Oncogene journal online. 42 Activating mutations of c-KIT occur in patients with gastrointestinal stromal tumors and systemic mastocytosis, as well as several other hematological malignancies. LNK binds the systemic mastocytosis-associated c-KIT mutant alleles, KITD816V and KITD816H. 48 Given its ability to interact with oncogenic c-KIT, and modulate c-KIT activity, we hypothesize that LNK may be occasionally mutated in mast cell disorders.
LNK mutations in myeloid neoplasms
The relevance of LNK to human disease is highlighted by the recent identification of LNK mutations in patients ( Figure 5 , Table 3 ). A study by Oh et al. 5 was the first to report LNK mutations in MPNs. A screen of 33 ET and PMF patients identified two mutations in exon 2 of LNK, which encodes part of the PH domain. Cell lines and primary patient samples expressing these mutant forms of LNK exhibited aberrant cytokine-dependent JAK/STAT signaling and proliferation. A follow-up study found that 11 of 341 (3%) samples from MPN patients had LNK mutations, including 3/61 (5%) ET, 3/75 (4%) PMF and 5/71 (7%) chronic myelomonocytic leukemia patients. 6 All the mutations localized to the PH domain of LNK. In a subsequent study of 61 patients with leukemia (MPN-blast phase), 9 heterozygous LNK mutations were identified in 8 patients (13%); of which 8 affected the PH domain. 7 LNK mutations were not detected in 78 additional patients with chronic phase MPNs, suggesting that LNK mutations may be involved in leukemic transformation. In addition, some samples had either a JAK2V617F or IDH mutation concurrent with LNK mutations. In a study of eight patients with idiopathic erythrocytosis (IE), two cases (25%) were found to have LNK PH domain mutations. 8 These patients do not have a predilection to develop leukemia, suggesting that Lnk mutation are not necessarily leukemogenic. More recently, several studies described LNK mutations outside the PH domain in MPN samples. 9, 11, 12 Most of the LNK mutations identified in MPNs are missense mutations targeting a 'hot spot' spanning residues Glu208-Asp234 in the PH domain. The PH domain is probably involved in membrane localization of LNK; and these mutations may lead to mislocalization of LNK to the cytoplasm. The mutations are predominantly heterozygous, raising the question of whether they contribute to MPN pathogenesis via haploinsufficiency and/or a dominant-negative effect. Lnk þ / À mice exhibit an intermediate MPN phenotype, consistent with a haploinsufficiency model. Alternatively, as the majority of LNK PH mutations leave the N-terminal dimerization domain intact, mutant LNK may bind and sequester WT LNK, resulting in a dominant-negative effect. Another question is whether specific mutations may contribute to different MPN disease phenotypes or responses to therapy. To begin dissecting the molecular mechanisms of LNK PH mutations, we analyzed the effect of different mutations on signaling pathways downstream of either WT or oncogenic TKs. 50 We found that LNK PH domain mutants have mild, variable, partial loss of function compared with WT LNK and did not have a dominant-negative effect. In addition, the mutants retain binding capacity for JAK2, as well as to several other known LNK targets.
Early T-cell precursor ALL is a subgroup of T-ALL, which is a neoplasm of early hematopoietic cells. Deep sequencing of 64 early T-cell precursor ALL patients identified 4 (6%) samples with LNK mutations, whereas no LNK mutations were found in nonearly T-cell precursor T-ALL cases. 13 This was the first report describing LNK mutations in lymphoid leukemia. We have sequenced the PH domain of LNK in 147 lymphoma samples (mantle cell lymphoma, peripheral T-cell lymphoma (PTCL) and adult T-cell leukemia/lymphoma cases) but could not detect any mutations. Based on the newly discovered mutations outside the PH domain, additional sequencing of the full-length LNK gene may be warranted. In rare cases LNK mutations were also detected in a number of solid tumors. [51] [52] [53] In addition to mutations, a nonsynonymous polymorphism (rs3184504, R262W ) in the LNK PH domain is associated with various autoimmune and cardiovascular disorders including type 1 diabetes, 54 62, 63 and myocardial infarction. 64 The R262W LNK polymorphism has also been associated with elevated peripheral blood white cells, eosinophils, lymphocytes and platelets, 64 as well as increased proliferation of monocytes in diabetic patients. 65 A recent functional study found that LNK R262W is associated with higher cytokine production and stronger activation of the NOD2 pathway (a critical pathway for mediating immune defense), suggesting that LNK might have a role in protection against bacterial infection. 66 In addition to LNK R262W, a nonsynonymous polymorphism (rs72650673, E400K) in the SH2 domain of LNK is associated with IE. 67 In summary, abnormal signaling in leukemia is often linked to activated TKs such as BCR/ABL1, JAK2 and FLT3. In recent years, the importance of aberrant negative feedback regulation is increasingly recognized as an alternative mechanism leading to deregulated TK activity in transformed cells. Although infrequently mutated, LNK, CBL and SOCSs, all negative regulators of cytokine signaling pathways, appear to have impotent roles in hematopoietic malignancies.
LNK AS A THERAPEUTIC TARGET
Given its role as a broad spectrum regulator of cytokine signaling in normal and pathological hematopoietic cells, LNK may be a promising therapeutic target for hematopoietic diseases, as well as a number of other disorders ( Figure 6 ). In addition, inhibiting LNK may augment expansion and engraftment of HSCs/HPCs. As more data become available from whole-genome sequencing studies, further associations between LNK and MPNs and possibly other malignancies may emerge. Moreover, as resistance to Table 3 for more details. LNK nonsynonymous W262R single-nucleotide polymorphism is located in the PH domain and is associated with autoimmune and cardiovascular diseases. A full colour version of this figure is available at the Oncogene journal online.
Adaptor protein LNK S Gery and HP Koeffler TK-targeted therapies continues to be a vexing problem, understanding the role of downstream signaling molecules such as LNK have in TK pathways may aid in the development of novel therapeutic approaches to overcome drug resistance. If indeed LNK functions as a tumor suppressor in leukemia, perhaps it can be a therapeutic target. In vitro studies demonstrated that retroviral expression of LNK or octa-arginine-mediated delivery of LNK suppresses hematopoietic leukemic cell proliferation. 48, 68 Nevertheless, gene therapy is still a daunting technical challenge and a more practical method to activate LNK might be through discovery of small molecules that can modulate its activity. Expansion of HSCs/HPCs and enhancement of engrafting potential is a therapeutic goal aimed to treat hematological malignancies or genetic diseases by transplantation. Loss of LNK enhances both cytokine-dependent ex vivo expansion and in vivo engraftment of HSCs/HPCs. [20] [21] [22] [23] Notably, even transient inhibition of LNK facilitated engraftment of HSCs/HPCs under nonmyeloablative conditions, leading to full reconstitution in immunodeficient mice. 21 In addition, human embryonic stem cells may provide an alternative source for transplantation. Knockdown of LNK increased the hematopoietic progenitors generated from human embryonic stem cells, suggesting that targeting LNK maybe a beneficial strategy for generation of clinically transplantable HSCs from human embryonic stem cells. 69 Together, these studies suggest that LNK is an excellent candidate for the genetic manipulation of HSC/HPC self-renewal in vivo and in vitro.
Murine models place Lnk as a potential therapeutic target in several other diseases. For example, LNK regulates integrin aIIbb3-mediated signaling in platelets and stabilizes developing thrombi in vivo. 27 LNK might therefore represent a safe therapeutic target for the treatment and/or prevention of cardiovascular disease. Another example is featured in a murine hindlimb ischemia model; Lnk-deficient EPCs more potently produced hindlimb perfusion recovery and ischemic neovascularization compared with Lnk-intact cells. 34 Similarly, Lnk -/-mice have augmented retinal neovascularization without an increase of pathogenic angiogenesis in an in vivo model of retinopathy. Further, the KSL fraction of murine BM represents a population of HSCs and EPCs. Administration of KSL cells to a murine spinal cord injury model promotes angiogenesis, astrogliosis, axon growth and functional recovery following injury. LNK-deficient KSL cells were even more effective in promoting these regenerative events. 35 In addition, in a murine bone fracture model, loss of LNK enhances the regenerative response during healing of a fracture by the mobilization and recruitment of HSCs/EPCs. 36 Moreover, LNK is also expressed in adult brain and is a negative regulator of brain neural stem cell proliferation after stroke induction in a murine model; raising the possibility that LNK may be a therapeutic target in the postischemic brain. 70 LNK is associated with an array of pathogenic conditions, as well as control of self-renewal of HSCs; thus Lnk-targeted interventions may be of considerable clinical value. However, whether LNK itself can be effectively targeted needs to be established; and if so, whether this will be more useful therapeutically than targeting of upstream TKs. Adaptor protein LNK S Gery and HP Koeffler CONCLUSION Research over the last decade clearly points to a critical role for LNK in hematopoiesis including the control of cytokine signaling and cell proliferation. Also, a growing body of evidence suggests that LNK is involved in mitigating the effects of hematopoietic transformation. Mutation or deregulation of LNK activity occur in several hematopoietic malignances boosting the notion that LNK is a tumor suppressor. Better understanding of this important adaptor protein will likely pave the way for novel therapeutic strategies to modulate critical signaling pathways in cancer and other disorders.
